Children with intense mood swings face greater risk of emotional overeating in adolescence

https://www.news-medical.net/news/20261030/Children-with-intense-mood-swings-face-greater-risk-of-emotional-overeating-in-adolescence.aspx Children with large mood swings are at greater risk for comfort eating in their teens. "Children who often experience strong and variable emotions may be at greater risk of developing emotional overeating later in life," says first author Francesca Parisi, a PhD research fellow at NTNU's Department of Psychology.

FDA approves ILUMYA for adults with active psoriatic arthritis

https://www.news-medical.net/news/20261030/FDA-approves-ILUMYA-for-adults-with-active-psoriatic-arthritis.aspx Sun Pharmaceutical Industries Limited announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).

Hemoadsorption may improve outcomes in severe poisoning cases

https://www.news-medical.net/news/20261030/Hemoadsorption-may-improve-outcomes-in-severe-poisoning-cases.aspx The WHO estimated over 800,000 suicide deaths in 2012, with poisoning a major concern. Three‑quarters of suicides occur in low‑ and middle‑income countries, with an estimated 30% related to pesticides. Organophosphates account for at least 40% of pesticides in India. For non‑pesticide overdoses, the Extracorporeal Treatment in Poisoning Workgroup (EXTRIP) has reviewed over 20 drugs and toxins and issued recommendations for extracorporeal therapy.

New FAIR Health platform maps chronic disease prevalence across the United States

https://www.news-medical.net/news/20261030/New-FAIR-Health-platform-maps-chronic-disease-prevalence-across-the-United-States.aspx Today, FAIR Health launches FAIR Health Atlas, a free epidemiological reporting platform incorporating data on the commercially insured population. Atlas is an online tool that can provide insights to policy makers, researchers and others wishing to understand chronic disease prevalence trends and geographic variation over time. Drawing on FAIR Health's repository of commercial healthcare claims (the nation's largest), Atlas visualizes chronic disease data across all 50 states and Washington, DC, revealing the areas facing the greatest health challenges. It also includes relevant social determinants of health (SDOH) that influence the risk factors for these diseases.

New database offers insights into psychedelic use outside clinical trials

https://www.news-medical.net/news/20261030/New-database-offers-insights-into-psychedelic-use-outside-clinical-trials.aspx Fireside Project today announced the publication of "The Fireside Database: Large-Scale Evidence from 25,419 Psychedelic Support Interactions" in Science Advances, providing researchers and policymakers with an unprecedented empirical window into psychedelic use and support outside clinical settings.

Skin organoids reveal how herpes simplex virus spreads between cells

https://www.news-medical.net/news/20261030/Skin-organoids-reveal-how-herpes-simplex-virus-spreads-between-cells.aspx Researchers at the Max Delbrück Center and University Medical Center Hamburg-Eppendorf have traced in skin organoids, how herpes simplex virus 1 infection progresses among neighboring skin cells, deepening our understanding. The work was published in Science Advances.

Nanoscale particle shows potential as customizable delivery vehicle for personalized cancer vaccines

https://www.news-medical.net/news/20261030/Nanoscale-particle-shows-potential-as-customizable-delivery-vehicle-for-personalized-cancer-vaccines.aspx A nanoscale particle with a unique structure, developed at MIT, holds potential as a customizable delivery vehicle for personalized cancer vaccines. The backbone of the vaccine is a modified, harmless bacteriophage called M13, which forms a nanofiber that can be coated with cancer antigens. By precisely controlling the density of those cancer proteins, the researchers found that they could create a vaccine that prevents the development of colon tumors in mice.

Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies Authors: Benedikt Westphalen, MD, PhD; Vivek Subbiah, MD

https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261031-OUS-HONC-shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk-cta

New Pathways in Antithrombotic Therapy Authors: Geoffrey D. Barnes, MD, MSc; Carolyn S. P. Lam, MBBS, PhD; Christian T. Ruff, MD, MPH

https://www.medscape.org/viewarticle/new-pathways-antithrombotic-therapy-2026a1000gtd?page=1&src=mkmcmr_driv_stan_mscpedu_261031-OUS-HONC-new-pathways-antithrombotic-therapy-2026a1000gtd-cta&uac=148436CN

Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD

Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_261031_12396549_#transcript-download-es Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=2&uac=148436CN&src=mkmcmr_driv_il_mscpedu_261031_&subtitle-lang-code=es

Pathology’s Digital Revolution Is Changing Diagnosis Nelly Abulata, MD, PhD, MBA; Saeed Asiry, MD

https://www.medscape.com/viewarticle/pathologys-digital-revolution-changing-diagnosis-2026a1001434?ecd=mkm_ret_261101_mscpmrk-OUS_ExcNews_etid8841097&uac=148436CN&impID=8841097 Nelly Abulata, MD, PhD, MBA: Welcome to Digital Health Pulse, where medicine meets technology and patients stay at the center. Hello, everyone. I'm Dr Nelly Abulata, a professor and consultant of diagnostic hematology at Cairo University's Medical School in Egypt, a digital health strategist working across global healthcare systems, and your host.

A European Blueprint for Rare Diseases: Towards an EU Action Plan for Rare Diseases October 2026

https://www.eurordis.org/publications/european-blueprint-for-rare-diseases/ On 15 October 2026, EURORDIS launched the European Blueprint for Rare Diseases, outlining the rare disease community’s proposals for the structure, priorities and implementation of a future EU Action Plan on Rare Diseases. Rare diseases collectively affect around 30 million people across Europe, making European cooperation essential to improving access to diagnosis, treatment and specialised care. Building on existing initiatives, including the European Reference Networks, Orphanet and ERDERA, the Blueprint sets out a shared vision for stronger coordination, addressing remaining gaps and ensuring more equitable access to care and expertise across Europe. EURORDIS is calling on the European Commission to propose an EU Action Plan on Rare Diseases, using the Blueprint as the rare disease community’s contribution to its design. Discover the European Blueprint for Rare Diseases and its proposals for a more coordinated European approach to rare diseases.

Executive Summary of the European Blueprint for Rare Diseases October 2026

https://www.eurordis.org/publications/executive-summary-european-blueprint-for-rare-diseases/ On 15 October 2026, EURORDIS launched the European Blueprint for Rare Diseases, outlining the rare disease community’s proposals for the structure, priorities and implementation of a future EU Action Plan on Rare Diseases. Rare diseases collectively affect around 30 million people across Europe, making European cooperation essential to improving access to diagnosis, treatment and specialised care. Building on existing initiatives, including the European Reference Networks, Orphanet and ERDERA, the Blueprint sets out a shared vision for stronger European coordination, addressing existing gaps and ensuring more equitable access to care and expertise across Europe. Discover the 18 priority actions proposed by EURORDIS across diagnosis, specialised healthcare, integrated care and social inclusion, data, research, and access to medicines and medical devices. These actions provide a roadmap towards a more coordinated, comprehensive and equitable European approach to rare diseases.

Principles for Managed Entry Agreements in the WHO European Region: Policy Framework October 2026

https://www.eurordis.org/publications/principles-for-managed-entry-agreements-in-the-who-european-region-policy-framework/ The World Health Organization’s Regional Office for Europe (WHO) recently developed a new set of principles to help countries improve access to innovative, high-cost medicines while supporting the financial sustainability of healthcare systems. The framework outlines the set of managed entry agreement (MEA) principles that were developed by WHO/Europe, National Institutes for Health and Care Excellence, Utrecht University and experts from NMP Work Package3. Our former Patient Engagement & Therapeutic Development Director, Maria Cavaller Bellaubi, was also involved in the creation of the Framework. The framework includes eight core principles, an uncertainty scale, a decision-making flowchart and a checklist. Together, these tools aim to improve transparency, guide negotiations and support countries in establishing or refining their approaches to managed entry agreements.

Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries October 2026

https://www.eurordis.org/publications/timing-and-rate-of-reimbursement-for-cystic-fibrosis-modulator-therapies-in-eu-countries/ This article, published in ScienceDirect, examines cross-country differences in timing and rate of reimbursement for Cystic modulator therapies (CFTR modulators) and explores the determinants of reimbursement timelines across Europe. Among the paper’s co-authors is our former Patient Engagement & Therapeutic Development Director, Maria Cavaller Bellaubi. Although CFTR modulators are authorised at EU level, decisions on reimbursement are made nationally, leading to differences in when people living with cystic fibrosis can access these treatments.

Webinar Series: Kickstart your advocacy Date: 26 November 2026, 4 PM CEST 📍 Where: Online #3 – Practical Advocacy: demystifying European institutions

Webinar Series: Kickstart your advocacy Date: 26 November 2026, 4 PM CEST #3 – Practical Advocacy: demystifying European institutions 📍 Where: Online Young people have an important role to play in shaping the future for the rare disease community. But finding your voice, navigating traditional advocacy spaces, and knowing how to turn your ideas into action isn’t straightforward. https://www.eurordis.org/webinar-series-kickstart-your-advocacy/ EURORDIS events https://www.eurordis.org/category/events/

Expert Dialogue on Cross-Border Healthcare October 2026 4 November,

On 4 November, the European Parliament Intergroup on Cancer and Rare Diseases and Giorgos Georgiou MEP, will convene an expert dialogue on how Europe’s cross-border healthcare framework can better meet the needs of people living with cancer and rare diseases. EURORDIS – Rare Diseases Europe, the European Cancer Organisation (ECO) and the European Society for Paediatric Oncology (SIOPE), form the Intergroup’s secretariat. https://www.eurordis.org/expert-dialogue-on-cross-border-healthcare/

REMEDi4ALL, EURORDIS is launching a Repurposing Bootcamp Date: 2-3 November 2026 📍 Location: Paris, France

https://www.eurordis.org/remedi4all-patient-repurposing-bootcamp/

Europe’s rare disease community sets out Blueprint for coordinated EU action October 2026

Europe’s rare disease community sets out Blueprint for coordinated EU action October 2026 15 October 2026, Paris – EURORDIS-Rare Diseases Europe has today launched the European Blueprint for Rare Diseases, setting out the rare disease community’s proposals for the structure, priorities and delivery of a future EU Action Plan on Rare Diseases. The proposed Plan would connect existing initiatives, close remaining gaps and strengthen delivery across Europe. https://www.eurordis.org/europes-rare-disease-community-sets-out-blueprint-for-coordinated-eu-action/

Making the Invisible Visible: New Brochure to Help Doctors and Families Recognize ROHHAD October 2026

https://www.eurordis.org/making-the-invisible-visible-new-brochure-to-help-doctors-and-families-recognize-rohhad/ Rapid-onset Obesity with Hypothalamic dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD) is a serious rare illness that usually strikes previously healthy children. It begins with rapid and unexplained weight gain, then failing breathing, unregulated body temperature, and misfiring hormones.